AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00766909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days.
Study NCT04706273 — intervention group
Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis
Description: Participants receiving the GORE® VIABAHN® Endoprosthesis
Study NCT01279551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% nitroglycerin ointment
Description: Local endoanal application 2 times a day
Study NCT01279551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine cloridrato 2.5% ointment
Description: Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
Study NCT03996954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alivecor recording
Description: Alivecor recording and ECG recording from the same patient in very close temporal proximity
Study NCT00766909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days.
Study NCT00766909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsules and isotonic saline
Description: For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days.
Study NCT03861052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT03861052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT04154007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests - urine output
Description: AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy.
Study NCT04181099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implant neck surface
Description: The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
Study NCT01487837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Description: Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
Study NCT01487837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human fibrinogen concentrate
Description: Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
Study NCT02340936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 15 mg)
Description: 3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study NCT02340936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 20 mg)
Description: 3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study NCT01713907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT03802201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Subcutaneous (SC)
Study NCT02336191 — intervention group
Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: living donor liver transplantation
Study NCT02331173 — intervention group
Intervention type: DRUG
Intervention: Dorzolamide 2% TID or brinzolamide 1% TID
Description: Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day
Study NCT03730870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics report
Description: Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
Study NCT01677676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1
Description: IM injection
Study NCT01677676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant
Description: IM injection
Study NCT02689544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention with static stretching
Description: Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
Study NCT02689544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention with Dynamic Stretching
Description: Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
Study NCT02689544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group volunteers no received intervention
Study NCT00255606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given in 3- or 4- week courses
Study NCT00255606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given in 3- or 4- week courses
Study NCT01209117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Capsule
Description: 200 mg GSK2248761 WBM capsule (reference) 2 X100mg
Study NCT01209117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet Formulation 1
Description: GSK2248761 WBM Tablet 200mg manufacturing process 1
Study NCT03556189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
Study NCT03552146 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
Study NCT03552146 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
Study NCT03559257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC.
Study NCT03559257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT01209117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet Formulation 2
Description: GSK2248761 WBM Tablet 200mg manufacturing process 2
Study NCT01209117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet Formulation 3
Description: GSK2248761 WBM Tablet 200mg manufacturing process 3
Study NCT01209117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 WBM Tablet
Description: GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
Study NCT03670550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Rebound ACL Brace
Description: ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
Study NCT04554329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bandage contact lens
Description: bandage contact lens
Study NCT02352428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Cancer Screening Training
Description: Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
Study NCT02758106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vest Airway Clearance System Model 105
Description: HFCWO for 15 minutes then sputum suction.
Study NCT01408030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.9%, 0.1 ml spray in each nostril bid
Study NCT01408030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 1% solution in saline, 0.1 ml spray in each nostril bid
Study NCT01408030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
Study NCT01408030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 10% solution in saline, 0.1 ml spray in each nostril bid
Study NCT02758106 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention
Description: CCPT for 15 minutes then sputum suction.
Study NCT01572844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Carbon Dioxide (FCO2) Laser
Description: At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
Study NCT01572844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
Study NCT03795688 — intervention group
Intervention type: OTHER
Intervention: Pregnancy
Description: Peripartum transition from pregnant to postpartum state
Study NCT01438853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-832
Description: Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
Study NCT02658357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Implant
Study NCT01438853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous dose of saline control
Study NCT01518010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play game
Description: Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
Study NCT03280290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood
Description: assessment pre-donation of hematopoietic stem cells (blood sample)
Study NCT04078061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MABA
Description: Adaptive, modular, behavioral intervention.
Study NCT04078061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EIBI
Description: Early Intensive Behavioral Intervention
Study NCT04252157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
Study NCT04252157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plesebo Taping
Description: An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
Study NCT04252157 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: no kinesio or tape will be applied
Study NCT02233556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50
Study NCT00666705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300 milligrams(mg) every 12 hours Days 6-11
Study NCT00666705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Study NCT00666705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Study NCT00666705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
Study NCT03259568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS
Description: 1-10 Hertz rTMS will be administered
Study NCT05393661 — intervention group
Intervention type: OTHER
Intervention: inpatient physical therapy poststroke
Description: routine care
Study NCT03078283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fiber food type
Description: In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
Study NCT00534287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Description: Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
Study NCT00534287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem, moxifloxacin
Description: Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
Study NCT01778335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy/thrombolysis
Description: Endovascular mechanical thrombectomy or thrombolysis
Study NCT04599894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 37.5mg Pregabalin + 75mg Pregabalin
Description: 37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
Study NCT04599894 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 75mg Pregabalin
Description: 75mg pregabalin postoperatively
Study NCT01389154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung biopsy using Always On EM Tip Tracked Device
Description: Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
Study NCT04971759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine 5%
Study NCT04971759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
Study NCT04971759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Levobupivacaine 5% + 1µg/kg fentanyl
Study NCT03080441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure stockings
Description: pressure stockings worn during dialysis throughout treatment period
Study NCT03080441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
Study NCT03080441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure stockings and midodrine
Description: combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
Study NCT03212612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: samples obtained by laparoscopy or punch biopsy for analysis by ELISA
Description: Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
Study NCT01026792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT01026792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01364207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated Coffee
Description: Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
Study NCT01364207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated Coffee
Description: Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
Study NCT02400840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
Study NCT02919501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (IV)
Description: 17 mg, solution for infusion, administered, over 2 hours as single dose
Study NCT03649373 — intervention group
Intervention type: PROCEDURE
Intervention: Noergaard technique
Description: The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
Study NCT02919501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (IV)
Description: Saline: isotonic sodium chloride, administered, over 2 hours as single dose
Study NCT02919501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vortioxetine (tablet)
Description: 10 mg, tablets, oral administration once daily for 15 days (open labelled)
Study NCT02919501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (tablet)
Description: 10 mg, tablets, oral administration once daily for 15 days (open labelled)
Study NCT01165554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
Study NCT02400840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI
Description: Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
Study NCT02400840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadobenic acid intravenous injection 0.2 ml/kg
Description: gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
Study NCT02400840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gadobenic acid intravenous injection 0.2 ml/kg
Description: gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
Study NCT00324428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day